Yazar "Bodur, Hafize" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: A real-life evidence from biostar nationwide registry
    (BMJ Publishing Group, 2023) Duruöz, Mehmet Tuncay; Bodur, Hafize; Ataman, Şebnem; Gürer, Gülcan; Akgül, Özgür; Çay, H. F.; Çapkın, Erol; Altan İnceoğlu, Lale
    Background: Association between spondyloarthritis and cardiovascular (CV) diseases is a complex issue with variable outcomes. Objectives: This study aimed to assess the prevalence rates of CV diseases and to analyze the impact of CV risk factors on CV disease in patients with spondyloarthritis. Methods: A multi-center cross-sectional study using BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory and clinical, data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2.The primary outcome was the prevalence rates of CV disease and CV risk factors in the overall group. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease.
  • Küçük Resim
    Öğe
    Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: A real-life evidence from biostar nationwide registry
    (BMJ Publishing Group, 2023) Duruöz, Mehmet Tuncay; Ataman, Şebnem; Bodur, Hafize; Çay, H. F.; Alkan Melikoğlu, Meltem; Akgül, Özgür; Çapkın, Erol; Gürer, Gülcan; Çevik, Remzi; Göğüş, Feride Nur; Kamanlı, Ayhan; Yurdakul, Fatma Gül; Yağcı, İlker; Rezvani, Aylin; Altan İnceoğlu, Lale
    Background: Patients with rheumatoid arthritis (RA) have increased morbidity and mortality due to cardiovascular (CV) comorbidities. Objectives: The association of CV diseases (CVD) and traditional CV risk factors have been debated, depending on patient and RA characteristics. This study aimed to find the prevalence of CVD and CV risk factors in patients with RA. Methods: A multi-center cross-sectional study was performed on RA patients using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry). Socio-demographic, clinical, and follow-up data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. Prevalence rates of CVD and traditional CV risk factors were the primary outcomes. Secondary outcomes were the differences in the clinical characteristics between patients with and without CVD.